Jump to content

Page values for "Timolol"

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringTimolol (maleate)
brandStringTimoptic (ophthalmic), Timoptic-XE (gel-forming once-daily), Istalol (once-daily 0.5%), Betimol; Blocadren (oral, discontinued in many markets); combination eye drops Combigan (with brimonidine), Cosopt (with dorzolamide)
structureFile
classesList of String, delimiter: ,[[:Category:Beta blockers|Beta blocker (non-selective)]] [[:Category:Antiglaucoma medicines|Antiglaucoma medicine]] [[:Category:Antihypertensives|Antihypertensive]] [[:Category:Migraine prophylactics|Migraine prophylactic]]
mechanismString
usesString'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"'
starting_doseStringOphthalmic: 1 drop 0.5% in affected eye(s) BID (or once daily for XE / Istalol). Oral hypertension: 10 mg PO BID, titrate to 60 mg/day. Migraine prophylaxis: 10 mg BID, titrate to 30 mg/day
preparationsStringTablets 5, 10, 20 mg; ophthalmic solution 0.25%, 0.5%; ophthalmic gel-forming solution 0.25%, 0.5% (Timoptic-XE)
fda_maxString60 mg/day (oral, hypertension); 0.5% BID (ophthalmic)
pill_idText
routesList of String, delimiter: ,Oral ophthalmic
onsetStringBP effect within hours (oral); IOP reduction within 30 minutes, full effect 1-2 weeks (ophthalmic)
durationString12 hours (oral BID); 24 hours (Timoptic-XE)
halflifeString~4 hours (oral)'"`UNIQ--ref-0000001B-QINU`"'
bioavailabilityString~50% (oral); systemic absorption from ophthalmic application is clinically meaningful via nasolacrimal drainage'"`UNIQ--ref-0000001C-QINU`"'
pregnancyStringLimited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalString[[USLegal:Prescription only|Rx-only]] in US